Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
David Mitchell, 67, says he ’s sure that Novartis’ Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He’s sure of something else, too: Novartis is charging too much.
LUNG cancer symptoms may only appear when the condition becomes more advanced, which may make it harder to treat. The number of people surviving one year with the condition rose to 38 per cent in 2015, according to the National Lung Cancer Audit. You should never ignore unexplained weight loss, which could be a sign of the condition.
Conclusions: The use of a hydrogel prior to salvage HDR-BT in a patient previously treated with HDR-BT is feasible and could help reduce the rectal exposure in the salvage setting. PMID: 29789766 [PubMed]
Conclusions: LDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients. PMID: 29789764 [PubMed]
Authors: Huo X, Huo B, Wang H, Wang L, Cao Q, Zheng G, Wang J, Chai S, Zhang Z, Yang K, Niu Y, Wang H Abstract Purpose: To evaluate intermediate-term outcomes after computed tomography (CT)-guided radioactive 125I seed implantation (CTRISI), and to determine prognostic variables associated with outcomes in patients with pulmonary metastases. Material and methods: Thoracic surgeons evaluated and performed implantation of 125I radioactive seeds under CT guidance or combined with surgical resection. Patients were monitored in the thoracic surgery clinic for recurrence and survival. Results: Fifty patients (31 ...
Conclusions: With appropriate patient selection and choosing as lowest dose per fraction as possible, HDR brachytherapy with customized surface molds yields good oncological and cosmetic results for the treatment of localized skin BCC and SCC. PMID: 29789760 [PubMed]
Conclusions: VBT alone is as effective as EBRT+VBT in ensuring loco-regional control and achieving comparable survival rates, with fewer toxic effects for patients with stage I intermediate- and high-risk endometrial carcinoma. The dose escalation did not make a difference in the survival rates and was like in the other major trials (PORTEC-2). PMID: 29789759 [PubMed]
Conclusions: This technique, although time-consuming, achieves good local disease control with a satisfactory toxicity profile in both early-stage and local recurrent breast cancer patients. It may be especially suitable for frail patients. PMID: 29789758 [PubMed]
CONCLUSIONS: Future cachexia trials would likely benefit from studying a single tumour type with earlier stage disease, with probably different dosage depending on the cancer type and its inflammatory profile. PMID: 29779814 [PubMed - in process]
Publication date: Available online 26 May 2018 Source:Methods Author(s): Tianle Ma, Aidong Zhang Defining subtypes of complex diseases such as cancer and stratifying patient groups with the same disease but different subtypes for targeted treatments is important for personalized and precision medicine. Approaches that incorporate multi-omic data are more advantageous to those using only one data type for patient clustering and disease subtype discovery. However, it is challenging to integrate multi-omic data as they are heterogeneous and noisy. In this paper, we present Affinity Network Fusion (ANF) to integrate multi-omi...
Conclusion Robotic surgical staging with dual docking in women with high risk endometrial cancer seems to be feasible with few complications. More studies are required to assess the safety of robotic surgery and its impact on survival.